A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

  • STATUS
    Recruiting
  • End date
    Mar 29, 2024
  • participants needed
    17
  • sponsor
    Janssen Research & Development, LLC
Updated on 9 May 2021
monoclonal antibodies
measurable disease
monoclonal antibody therapy
monoclonal protein
immunoglobulin
ibrutinib

Summary

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory waldenstrom's macroglobulinemia.

Details
Condition Waldenstrom's Macroglobulinemia, Lymphoproliferative Disorder, Lymphoproliferative disorders, Waldenstrom Macroglobulinemia
Treatment Ibrutinib
Clinical Study IdentifierNCT04042376
SponsorJanssen Research & Development, LLC
Last Modified on9 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note